Assessing the use of low-molecular-weight heparins for venous thromboembolism prophylaxis in internal medicine patients;Evaluación de la utilización de heparinas de bajo peso molecular como profilaxis de tromboembolismo venoso en pacientes de medicina interna

Farmacia Hospitalaria

Volumn 28, Issue 6, 2004, Pages 402-409

  Villar Fernández, Isabel ^a   Urbieta Sanz, E ^a   Arenere Mendoza, M ^a   Lopez Larramona G ^a   Marcilla Cordoba F ^a   Rabanaque Hernandez M J ^b  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

Embolism and thrombosis; Heparin low molecular weight; Medical patients

Indexed keywords

DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN;

ADULT; AGED; ARTICLE; BED REST; CHI SQUARE TEST; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIABETES MELLITUS; DRUG USE; DYSLIPIDEMIA; FEMALE; HEART DISEASE; HUMAN; HYPERTENSION; INTERNAL MEDICINE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; STANDARD; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; EVALUATION STUDIES; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 13444267825     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107 (23 Supl. 1): 14-8.
2. Thromboembolic Risk Factors Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. BMJ 1992; 305: 567-74.
3. Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M, Buchmüller A, Juillard-Delsart D, et al. Prevention of venous thromboembolism in Internal medicine with unfractionated or low-molecular-weight-heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000; 83: 14-9.
4. Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 1995; 108: 978-81.
5. Sixth ACCP Consensus Conference on Antithrombotic Therapy. Prevention of Venous Thromboembolism. Chest 2001; 119 (Supl. 1): 132S-175S.
6. Prevention of venous thromboembolism. International Consensus Statement Guidelines compiled in accordance with the scientific evidence. Int Angiol 2001; 20 (1): 1-37.
7. Anderson FA Jr, Wheeler HB, Goldberg RJ. Prospective study of the impact of continuing medical education and quality assurance programmes on use of prophylaxis of VTE. Arch Int Med 1994; 154: 669-77.
8. Salzman EW, Hirsch J. Prevention of venous thromboembolism. In: Colman RW, Hirsch J, Marder V, Salzman EW, eds. Hemostasis and thrombosis: basic principles and clinical practice. New York: Lippincott, 1986.
9. Rocha E, Díaz S, Alegría E. Heparinas de Bajo Peso Molecular. Madrid: Acción Médica, 2001. p. 3-49.
10. Rocha E, Páramo JA, Sarrá J. Heparinas de Bajo Peso Molecular. Med Clin 1993; 100: 620-7.
11. Rocha E, Martínez E, Monreal M. Manejo Práctico del paciente con tromboembolismo venoso. Madrid: Acción Médica, 2002. p. 1-42.
12. Protocolo de Prevención de la Enfermedad Tromboembólica Venosa. Zaragoza: Hospital Universitario Miguel Servet, 1998.
13. Mismetti P, Juillard-Delsart D, Tardy B, Laporte-Simitsidis, Decousus H. Evaluation du risque thromboembolique veineux en milieu médical. Thérapie 1998; 53: 565-70.
14. Alonso Ortiz del Río C, Medrano Ortega FJ, Romero Alonso A, Villar Conde E, Calderón Sandubete E, Marín León I, et al. Guía PRETE-MED 2003. Guía de profilaxis de enfermedad tromboembólica en patología médica. Córdoba: SADEMI, 2003.
15. Bergovist D. Low molecular weight heparins. J Int Med 1996; 240: 67-72.
16. Cohen AT. Venous thromboembolic disease management of the nonsurgical moderate-and-high-risk patient. Seminars in Hematology 2000, 37 (3, Supl. 5): 19-22.
17. Harenberg J. Risk assessment of venous thomboembolism in medical patients. Seminars in Hematology 2000; 37 (3, Supl. 5): 3-6.
18. Haas S. Low molecular weight heparins in the prevention of venous thrombombolism in nonsurgical patients. Seminars in thrombosis and hemostasis 1999; 25 (Supl. 3): 101-5.
19. Samama MM, Cohen AT, Darmon JY, Desjardins, L, Eldor A, Janbon C, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999; 341: 793-800.
20. Hull RD, Rascob GE, Rosenbloom D, Pineo GF, Lerner RG, Gafni A, et al. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight- heparin vs intravenous heparin: an economic perspective. Arch Intern Med 1997; 157: 289-94.